Clinical controversies over antiviral therapy for patients in the immune-tolerant phase of hepatitis B virus infection
To achieve the goal of"eliminating viral hepatitis as a public health hazard by 2030",extensive screening,active prevention,and antiviral therapy are currently recommended for chronic hepatitis B virus(HBV)infection;however,no consensus has been reached on whether to initiate antiviral therapy for patients in the immune-tolerant phase of chronic HBV infection.Some experts believe that patients in the immune-tolerant phase tend to have a stable liver immune microenvironment,with a low risk of disease progression and poor response to treatment,and thus it is not recommended to initiate antiviral therapy.However,various other studies have shown that patients in the immune-tolerant phase still have inflammatory damage in the liver,with a risk of disease progression and a high level of cost effectiveness,and therefore,some experts suggest that antiviral therapy should be actively initiated for patients in the immune-tolerant phase.This article performs a literature review of the definition of patients in the immune-tolerant phase of chronic HBV infection and the advantages and disadvantages of antiviral therapy and conducts a preliminary analysis based on previous studies,in order to accumulate the evidence for whether to initiate antiviral therapy in the immune-tolerant phase of chronic HBV infection and lay a foundation for standardized clinical diagnosis and treatment of patients in the immune-tolerant phase.
国家科技期刊平台
NSTL
万方数据
